Enterprise Value
-105M
Cash
386.9M
Avg Qtr Burn
-45.59M
Short % of Float
34.76%
Insider Ownership
36.80%
Institutional Own.
57.18%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Imvotamab (IGM-2323) (CD20 x CD3) Details Autoimmune disease, Systemic lupus erythematosus | Phase 1b Initiation | |
Imvotamab (IGM-2323) (CD20 x CD3) Details Autoimmune disease, Rheumatoid arthritis | Phase 1b Initiation | |
Aplitabart (IGM-8444) (DR5 agonist) + FOLFIRI +/- bevacizumab Details Solid tumor/s, Cancer, Colorectal cancer | Phase 1 Data readout | |
IGM-7354 (IL-15 x PD-L1) Details Solid tumor/s, Cancer, Hematologic malignancies | Phase 1 Update | |
IGM-2644 (CD38 x CD3) Details Multiple myeloma | Phase 1 Update | |
Aplitabart (IGM-8444) + venetoclax & azacytidine Details Acute myeloid leukemia | Phase 1 Update | |
Aplitabart (IGM-8444) + birinapant Details Solid tumor/s, Hematologic malignancies | Phase 1 Update | |
Imvotamab (IGM-2323) (CD20 x CD3) Details Non-Hodgkin lymphoma, Cancer, Chronic lymphocytic leukemia | Failed Discontinued | |
IGM-6268 Details Solid tumor/s, Cancer | Failed Discontinued |